Status:
UNKNOWN
Phenomics and Genomics of Clozapine Pharmacotherapy
Lead Sponsor:
Jurjen Luykx
Conditions:
Schizophrenia Spectrum and Other Psychotic Disorders
Eligibility:
All Genders
18+ years
Brief Summary
A burgeoning body of research has pointed to increased efficacy of clozapine (CLZ) over other antipsychotics in schizophrenia (SCZ). On the other hand, safety concerns likely cause underutilization ac...
Detailed Description
Rationale Clozapine (CLZ) is generally prescribed if at least two trials of antipsychotic agents have not led to satisfactory clinical improvement, thereby implying that patients on CLZ generally suff...
Eligibility Criteria
Inclusion
- he/she currently uses CLZ or he/she has used CLZ in the past/will use CLZ
- he/she has received a diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder or psychotic disorder NOS.
- his/her age must be ≥18 years old
- he/she must be able to speak and read the language of the Informed Consent (differs per country)
- he/she must be mentally competent and have decisional capacity with regard to a decision to participate in the current study
Exclusion
- admission to a psychiatric unit involuntarily (not all countries)
- a history of Parkinson's disease
Key Trial Info
Start Date :
January 19 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
2500 Patients enrolled
Trial Details
Trial ID
NCT03253367
Start Date
January 19 2016
End Date
December 1 2021
Last Update
March 5 2020
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University Innsbruck
Innsbruck, Austria, 6020
2
Niuvanniemen hospital
Kuopio, Finland, 70240
3
LMU Munich
München, Munich, Germany, 80336
4
Charité Universitätsmedizin Berlin
Berlin, Germany, 10117